Valeant May Actually Be A Good Investment Right Now Nov. 21, 2014 10:12 AM ET | by Abba's Aces | about: vrx Summary The company itself certainly seems to think so as it just issued a new $2 billion share repurchase program. The stock is undervalued with respect to 2015 earnings estimates and has great near- and long-term earnings growth potential. The financial efficiency ratios can use a little bit of work, but they aren't too bad.
Seeking Alpha is an absolutely garbage investing website. For every intelligent, well thought out, and well-researched piece, there are 17 horribly constructed bits of trash written by people who clearly have never worked a day on Wall Street in their life.
Abba's Aces on Seeking Alpha is not a person giving much depth to his analyses. (He saw the $2-billion VRX stock buyback announcement and got all excitable and starry-eyed, not realizing that the Valeant board authorizes a buyback like this every year, but then never follows through.) A.A. posts a new "analysis" of a different stock every day. Here is his self-description from his profile: "...I love the financial world because it is like one big puzzle and I hope we, the Seeking Alpha Community, help each other out to solve the puzzle to help us realize out dreams." Yikes! Would you take financial advice from an analyst like that? The only puzzle is why anyone invests in Valeant Pharmaceuticals in the first place. The person consistently following Valeant on Seeking Alpha in-depth is Uncommon Profit Investor, but all his/her analysis of VRX is uniformly bear-oriented. If you want to hear positive things about Valeant, you will have to go elsewhere; the folks at Motley Fool seem to like VRX. Caveat emptor.
